• Bone marrow mesenchymal stromal cells preserve CML stem cells from elimination following tyrosine kinase inhibitor treatment.
Introduction
Chronic myeloid leukemia (CML) originates from a primitive hematopoietic cell that is transformed by the BCR-ABL oncogene. 1 The deregulated tyrosine kinase activity of the BCR-ABL protein leads to increased proliferation, reduced apoptosis, and disturbed interaction with the extracellular matrix, resulting in abnormal expansion of myeloid progenitors and differentiated myeloid cells. The BCR-ABL tyrosine kinase inhibitors (TKIs) imatinib (IM), nilotinib, and dasatinib are highly effective in treatment of CML, resulting in complete cytogenetic responses and major reductions in BCR-ABL transcript levels in most chronic phase (CP) CML patients. 2, 3 Conversely, cessation of drug treatment leads to disease recurrence in most CML patients, and the fraction of patients in whom TKI treatment can be discontinued remains low. 4 A persistent population of leukemia stem cells (LSCs) is the likely source of relapse after TKI discontinuation. 5 Quiescent CML LSCs are especially resistant to TKI-induced apoptosis. Because TKI treatment effectively inhibits BCR-ABL kinase activity in primitive CML LSCs, there is increasing interest in identifying BCR-ABL kinase-independent mechanisms that may contribute to preservation of LSCs during TKI treatment. [6] [7] [8] [9] Normal hematopoietic stem cells (HSCs) localize to specialized microenvironmental niches in the bone marrow (BM) that provide critical signals to regulate HSC numbers and quiescence and support HSC preservation. 10 Although less well studied, there is some evidence that LSC generation and propagation may also be supported by microenvironmental cells. 11 In addition, BM stromal cells or extracellular matrix may protect leukemia cells from the effects of chemotherapy and small molecule-targeted therapies. [12] [13] [14] For example, the VLA-4 and CXCR4 receptors (required for normal HSC homing and retention to the hematopoietic niche) have been found to be important for acute myeloid leukemia LSC homing and growth, 12, 15 and blockade of these receptors can enhance acute myeloid leukemia LSC sensitivity to chemotherapy. Moreover, antibody-mediated targeting of the CD44 adhesion receptor can prevent trafficking of CML LSCs to the BM and promote LSC differentiation. 16, 17 Culture of CML cell lines with stromal cell-conditioned medium or with fibronectin is reported to result in resistance to IM. 18, 19 In turn, IM treatment increases CXCR4-mediated migration of CML cell lines to BM mesenchymal stromal cells (MSCs) and results in increased cell cycle arrest and survival of quiescent cells. 20 Although these results with cell lines and murine models suggest that microenvironmental interactions could protect CML cells from TKI treatment, the role of the BM stromal microenvironment in protecting primary human CML LSCs from TKI treatment and the underlying molecular interactions are not well studied. Two recent studies have indicated that culture of primary CML CD34
1 cells with conditioned media from or in direct contact with BM stroma can protect CML cells from TKI-induced cell death or inhibition of colony formation. 21, 22 However, these studies have not evaluated microenvironmental interactions with phenotypically or functionally defined primitive CML stem/progenitor cells.
Previous studies have indicated a potential role for the cell-cell adhesion receptor N-cadherin in HSC regulation by BM osteoblasts and resistance of leukemia cells to therapy. 23, 24 Although recent reports indicate that N-cadherin is not required for regulation of murine HSCs, 25, 26 the role of N-cadherin in human hematopoiesis is not well studied. 14, 24, 27 Cadherins mediate adhesion through homotypic interaction between cell surface receptors. Cadherins can associate with b-catenin leading to their stabilization, linkage to the actin cytoskeleton, and enhanced cell-cell adhesion. 28, 29 Wnt ligands in the microenvironment can activate b-catenin signaling through engagement of Frizzled and LRP6 receptors. Canonical Wnt signaling results in stabilization and nuclear translocation of b-catenin, complex formation with tissue-coding factor/ leukokinesis-enhancing factor (TCF/LEF), and transcription of target genes. 30 b-catenin signaling may regulate normal HSC selfrenewal and hematopoietic reconstituting ability. 31 Enhanced Wntb-catenin activity is reported to contribute to LSC transformation in blast crisis CML, although its role in CP CML is less clear. 32, 33 In a BCR-ABL transduction-transplantation model, expression of BCR-ABL in b-catenin-deleted HSCs resulted in reduced LSC self-renewal and leukemia development. 34, 35 Deletion of b-catenin in established leukemia synergized with IM to eliminate CML stem cells. 36 Potential mechanisms underlying increased b-catenin in CML cells include BCR-ABL-mediated b-catenin phosphorylation leading to protein stabilization and activation of nuclear signaling 37 and reduced b-catenin degradation related to GSK3b inactivation downstream of BCR-ABL, 38 or missplicing of GSK3b as reported in blast crisis CML LSCs. 37 However, the role of exogenous microenvironmental Wnt in activating b-catenin signaling in CML LSCs has not been evaluated. In this study, we determined whether human BM MSCs affected the survival, proliferation, and in vitro and in vivo growth of primitive CML stem/progenitor cells exposed to TKI treatment. In this context, we evaluated the roles of N-cadherin and exogenous Wnt-b-catenin signaling in modulating response to TKI treatment. 
Methods

Cell culture
Human reverse transcriptase (hTERT) -immortalized primary human marrow MSCs were maintained in RPMI 1640 with 10% fetal bovine serum for no more than 5 passages. MSCs were subcultured in tissue culture plates (Falcon; BD Biosciences, San Jose, CA) until confluent followed by irradiation at 20 Gy. CD34 1 cells were cultured in the presence or absence of irradiated MSCs at 37°C with 5% CO 2 in serum-free expansion medium (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with growth factors (GFs) at concentrations similar to those found in stroma-conditioned medium from long-term BM cultures (granulocyte-macrophage colony-stimulating factor 200 pg/mL, granulocyte colony-stimulating factor 1 ng/mL, stem cell factor 200 pg/mL, leukemia inhibitory factor 50 pg/mL, macrophage inflammatory protein-1 200 pg/mL, and interleukin-6 1 ng/mL). Stock solutions of the TKIs IM, nilotinib (Novartis Pharmaceuticals, East Hanover, NJ), and dasatinib (Bristol-Myers Squibb, New York, NY) were prepared in dimethylsulfoxide and stored at -20°C. IM, nilotinib, and dasatinib were added at concentrations of 5 mM, 5 mM, and 0.15 mM, respectively.
Apoptosis, proliferation, cell cycle, and colony-forming cell assays
To assess apoptosis, cells from CML patients and healthy controls (n 5 3 each) were cultured in the presence or absence of MSCs and TKIs for 96 hours, then labeled with Annexin V-PE (BD Biosciences PharMingen, San Diego, CA), and analyzed by flow cytometry (FACScalibur; BD Biosciences). Apoptotic cells were defined as Annexin V-PE
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. Proliferation was assessed by labeling cells with 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR), followed by culture for 96 hours with or without MSCs and TKIs. At the end of the culture period, CFSE levels were analyzed by flow cytometry. ModFit software (Verity, Topsham, ME) was used to fit the data, determine the percentage of cells in each generation, and generate a proliferation index. The position of the parent generation was set on the basis of an aliquot of cells treated with 4% paraformaldehyde immediately after sorting. For cell cycle analysis, cells were labeled with Ki67 and 4,6 diamidino-2-phenylindole and analyzed by flow cytometry. For colonyforming capacity assays, CD34
CD38
2 and CD34 1 CD38 1 cells cultured with or without TKIs and MSCs were plated in methylcellulose progenitor culture, and burst-forming unit-erythroid and colony-forming unit-granulocyte and macrophage cells were counted after 14 days.
Engraftment of human cells in immunodeficient mice
CML CD34
1 cells (2 3 10 6 cells per mouse) from 3 newly diagnosed CP CML patients were cultured for 96 hours with and without MSCs and IM. Subsequently, all cells were harvested and transplanted via tail vein injection into 8-week-old sublethally irradiated (3 Gy) NSG mice (The Jackson Laboratory, Bar Harbor, ME). Mice were euthanized after 4 or 10 weeks, and marrow contents of femurs, spleen cells, and blood cells were obtained. Human cell engraftment was assessed by labeling with anti-human CD45 antibody and analyzed by flow cytometry. Specific cell subsets were detected by using antibodies to human CD34, CD33, CD11b, CD71, CD3, and CD19. BCR-ABL messenger RNA (mRNA) levels in marrow cells obtained from mice were evaluated by quantitative polymerase chain reaction (Q-PCR).
Evaluation of adhesion and N-cadherin
Adherent and nonadherent cells were separated by using a standardized wash procedure. Plates were shaken well, and nonadherent cells were collected, 39 Cells were analyzed for apoptosis, intracellular signaling, and Q-PCR.
Evaluation of Wnt-b-catenin reporter activity
A b-catenin-activated reporter (BAR) Wnt-b-catenin reporter system was used. The reporter construct contains a concatemer of 12 TCF response elements separated by distinct 5-base linkers that drive Wnt-responsive transcription of a Venus enhanced yellow fluorescent protein variant. 40 This reporter was inserted into a lentivirus plasmid expressing red fluorescent protein (RFP) via a spleen focus-forming virus promoter (pBARvr). A control reporter (pfuBARvr) has a 2-base substitution in each TCF binding site. Infectious lentivirus vector stocks were used to transduce CML CD34 Slides were examined by using a Zeiss upright LSM 510 2-photon confocal microscope.
Real-time Q-PCR analysis
Total RNA was extracted by using the RNAeasy Mini Kit (Qiagen, Valencia, CA). First-strand complementary DNA was synthesized by using Superscript III First-Strand Kit (Invitrogen, Grand Island, NY). Q-PCR analysis for detection of BCR-ABL transcripts was performed in triplicate by using a real-time TaqMan assay and the ABI Prism 7700 sequence detector (Applied Biosystems, Foster City, CA), as previously described.
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BCR levels were measured as internal controls. Results were expressed as a BCR-ABL:BCR ratio. Q-PCR analysis was also performed for detection of N-cadherin, cyclin D1, c-Myc, and peroxisome proliferator-activated receptor delta transcripts, and glyceraldehyde 3-phosphate dehydrogenase and b-actin were measured as internal controls (supplemental Table 1 ).
Results were expressed as a ratio to glyceraldehyde 3-phosphate dehydrogenase or b-actin.
Microarray analysis
RNA was obtained from CML CD34 1 cells treated with or without IM (5 mM) and MSCs for 96 hours (n 5 3 each), aand then amplified, labeled, and hybridized to GeneChip 1.0 arrays (Affymetrix, Santa Clara, CA). Microarray data analysis was performed by using R (version 2.9; www.rproject.org) with genomic analysis packages from Bioconductor (version 2.4; www.bioconductor.org). The 33 297 probes represented on the microarray were filtered by cross-sample mean and for a standard deviation of greater than the 25% quantile, yielding 18 624 probes representing 12 553 genes. Linear regression was used to model the gene expression with a 2 3 2 factorial design and matched samples. Differentially expressed genes were identified by calculating the empirical Bayes-moderated t statistic, and P values were adjusted by false discovery rate (FDR) using the LIMMA package (Bioconductor). Gene set enrichment analysis (GSEA) was performed by using GSEA software version 2.04 (http://www. broadinstitute.org/gsea/) to detect enrichment of predetermined gene sets using t scores from all genes for 1263 gene sets in the C2 (curated gene sets) category from the Molecular Signature Database (MsigDB). 41 For significant gene sets related to the Wnt-b-catenin and cadherin pathways, leading-edge genes commonly enriched in these sets were analyzed. Heatmaps were plotted to show contrasts among the different treatment groups.
Western blotting
CD34
1 cells cultured with or without IM and MSCs for 48 to 96 hours were lysed in buffer containing 0.5% Nonidet P-40 (Sigma Diagnostics) and 0.5% sodium deoxycholate supplemented with phenylmethylsulfonyl fluoride (1 mM/L), protease inhibitor mixture, and phosphatase inhibitors (50 mM/L sodium fluoride, 1 mM/L sodium vanadate; all from Sigma Diagnostics). For nuclear cytoplasmic fractionation, cells were lysed in hypotonic buffer for 5 minutes, gently agitated for 1 minute on ice, and centrifuged at 13 000 rpm at 4°C for 10 seconds. Supernatants were collected as the cytoplasmic extract. After washing with hypotonic buffer, nuclear pellets were incubated in highsalt buffer at 4°C for 30 minutes, and supernatants were collected as nuclear extracts after centrifugation at 13 000 rpm at 4°C for 5 minutes. 42 Proteins were resolved on 4% to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to nitrocellulose membrane. Primary antibodies used were anti-phospho-Crkl (Cell Signaling, Danvers, MA), anti-N-cadherin (cat:AF6426; R&D Systems), anti-Ncadherin (3B9; Invitrogen), anti-b-catenin (14/b-catenin; BD Biosciences), anti-p-GSK3b (S9), anti-p-AKT, anti-actin (Cell Signaling), and antitubulin and anti-Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA). Horseradish peroxidase-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). Antibody detection was performed by using the SuperFemto kit (Pierce Biotechnology, Rockford, IL).
Duolink in situ proximity ligation assay
In situ proximity ligation assay (PLA) technology was used to locate and quantify interaction of N-cadherin and b-catenin, using the Duolink kit (Olink Biosciences, Uppsala, Sweden). 43 CML CD34 1 cells cultured with or without MSCs and IM for 96 hours were dropped on poly-L-lysinecoated slides, fixed, permeabilized, and incubated with sheep anti-human/ anti-mouse/anti-rat N-cadherin (cat:AF6426; R&D Systems) and mouse anti-human b-catenin (14/b-catenin; BD Biosciences) antibodies. After washing, cells were incubated with species-specific secondary antibodies, PLA probe anti-goat plus, and PLA probe anti-mouse minus, each with attached unique short DNA strands that can interact when in close proximity (,40 nm) through subsequent addition of 2 circle-forming DNA oligonucleotides. The oligonucleotides were joined by enzymatic ligation, amplified via rolling circle amplification using a polymerase, which resulted in several-hundredfold replication of the DNA circle, and labeled with 
oligonucleotide probes to highlight the product. The resulting amplification product was seen as a bright dot by using fluorescence microscopy.
Statistical analysis
Data obtained from independent experiments were reported as the mean plus or minus standard error of the mean. Significance levels were determined by Student t test analysis. Figure 1B) .
Results
BM
MSC coculture resulted in a modest increase in normal progenitor proliferation ( Figure 1C-D Figure 1B) . Coculture with MSCs significantly reduced apoptosis of both nondividing (CFSE bright) and dividing (CFSE low) CML CD34 1 CD38 2 cells after IM treatment ( Figure 1E-F) and increased the proportion of nondividing cells with or without IM treatment ( Figure 1G ). MSC coculture also resulted in a significantly enhanced colony-forming capacity of TKI-treated CML CD34 1 CD38 1 and CD34 1 CD38 2 cells compared with TKI treatment without MSCs ( Figure 1H ). MSC coculture did not result in significantly different effects on colony formation from CML CD34 1 CD38 2 cells compared with CD34 glyceraldehyde 3-phosphate dehydrogenase; ns, not significant. n 5 3. *P , .05; **P , .01; ***P , .001.
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Since N-cadherin has been shown to contribute to resistance of leukemia cells to therapy, we evaluated its role in MSC-mediated protection of CML stem/progenitor cells. 23, 24 In both normal and CML samples, N-cadherin was expressed at higher levels in CD34
1
CD38
2 compared with CD34 1 CD38 1 cells (Figure 3E-F) .
However, cell surface N-cadherin expression and N-cadherin mRNA were lower in CML compared with normal CD34 1 cells,
CD34
1 CD38 2 cells, and CD34 1 CD38 1 cells (Figure 3E-F) . We observed increased cell surface N-cadherin expression and Ncadherin mRNA expression in CML cells treated with IM in the presence of MSCs compared with untreated controls, IM alone, or MSCs alone ( Figure 3G-H) . Increased N-cadherin mRNA expression was restricted to MSC-adherent cells ( Figure 3H ). We used anti-N-cadherin blocking antibodies or anti-N-cadherin short cyclic HAV peptide (NCDH) to block N-cadherin interactions. As with CML CD34 1 cells, we also saw increased expression of b-catenin and N-cadherin ( Figure 4H ; supplemental Figure 3B ) and of Wnt target genes in normal CD34
1 cells cocultured with MSCs ( Figure 4I ).
Microarray analysis
We evaluated the effect of IM and MSC treatment on gene expression in CML CD34 Figure 5C ; Table 1 ). We identified the leading edge genes that contributed to enrichment of cadherin and catenin gene sets in CML CD34 1 cells cultured on MSCs.
Expression of these genes with different treatments is shown in Figure 5D and Figure 5E , respectively. N-cadherin-related genes upregulated by MSC coculture included extracellular matrix proteins VCAN, SPOCK1, COL6A3, and COL1A2; regulators of cell development EPNA1 and EPHB2; cytoskeleton regulators ACTA2, MICAL2, and MAP1B; apoptosis regulators, including TSC22D, BIRC3, and GREM1; and transcription factors KLF9, CREB3L1, BHLHE41, TSC22D3, and TCEA2. Wnt-b-catenin pathway genes upregulated by MSC coculture included WNT5B; the Wnt receptors FZD3, FZD4, FZD7, and LRP5; regulators of Wnt signaling BTRC, NLK1, FRAT1; the Wnt effector LEF1; and the Wnt target genes MYC and CCND1. 
Discussion
BCR-ABL expressing LSCs persist in CML patients receiving TKI treatment, despite effective inhibition of BCR-ABL tyrosine kinase activity. 6, 7, 9 LSCs are exposed to TKI in the context of the BM microenvironment, and our results show that BM-derived MSCs protect CML stem and progenitor cells from TKI-mediated cell death and depletion. The supportive effects of MSCs extend to both dividing and nondividing cells. MSC enhanced the proportion of nondividing CML cells, maintained CD34
1 expression, and enhanced retention of CML stem cells with NSG mouse repopulating capacity in the presence and the absence of TKI. Gene expression analysis confirmed that MSC coculture induced similar patterns of gene expression in the presence or absence of IM.
Our observation that N-cadherin-mediated adhesion plays an important role in protection of CML stem/progenitor cells from TKI treatment by BM MSCs reveals a novel and previously unrecognized mechanism of resistance of CML stem/progenitor cells to TKI treatment. The role of N-cadherin in HSC regulation has been controversial. Although initially reported to play an important role in murine HSC adhesion to osteoblasts and maintenance of HSC quiescence, subsequent studies using knockout mice have not supported an important role for N-cadherin in murine HSC function. 23, 25, 26, 47 Indeed, we could not detect N-cadherin mRNA expression in purified murine HSCs (data not shown). In contrast, but consistent with previous reports, 27 we found that N-cadherin was expressed on human stem/progenitor cell populations, indicating species-dependent differences in expression and function of Ncadherin between human and murine HSCs. independent mechanism of resistance to TKI treatment in human CP CML stem/progenitor cells. Cadherin cytoplasmic domains bind to submembranous b-catenin, which in turn is linked to the actin cytoskeleton. Cadherin receptor association with the cytoskeleton is necessary for stabilization of cell-cell adhesion. However, the role of N-cadherin and b-catenin interactions in regulating HSC growth is not well studied. 29, 45, 48, 49 We observed increased cytoplasmic N-cadherin-bcatenin complex formation in IM-treated CML CD34
1 cells cultured with MSCs, which could contribute to increased N-cadherin--mediated adhesion to MSCs. Although cadherins are reported to modulate Wnt-b-catenin signaling by sequestering b-catenin at the cell surface, which prevents translocation to the nucleus, 49 we found that N-cadherin-mediated adhesion to MSCs was associated with increased expression of b-catenin target genes in CML progenitors. Since secreted Wnts are bound to the cell surface or extracellular matrix, physiological Wnt signaling requires close adhesion of stem/ progenitor cells to MSCs. The critical role for N-cadherin in MSCmediated Wnt signaling may be related to its role in adhesion of CML progenitors to MSCs. Another possibility is that b-catenin in complex with N-cadherin in adherent cells may be protected from degradation and may remain available for activation by exogenous Wnt ligands. 49 Previous studies have suggested a potential role for the tumor microenvironment in protecting leukemia cells from the effects of drug therapy. 14, 18, 19, 50 However, it has been unclear whether such interactions could determine resistance of human CML LSCs to TKI treatment. With an increasing number of CML patients receiving continuous TKI treatment, concerns regarding high financial burden, long-term side effects, and loss of compliance have generated interest in developing approaches to target residual LSCs to facilitate cessation of treatment and achieve cures. Our results reveal a close interplay between microenvironmental signals mediated by N-cadherin and Wnt-b-catenin in protecting CML stem/progenitor cells during TKI treatment. These results elucidate a novel, previously unrecognized mechanism of resistance of CML stem/progenitor cells to TKI treatment and support further testing of measures aimed at interfering with N-cadherin-mediated interactions or Wnt secretion or signaling from the microenvironment to promote eradication of residual malignant cells.
